Thermo Fisher Scientific is buying Brammer Bio of Cambridge, Mass., for about $1.7 billion as the giant Waltham, Mass.-based laboratory equipment supplier moves into the fast-growing area of gene therapy.

Brammer Bio makes viral vectors that are used to deliver genetic material into defective cells in the hopes of treating or possibly even curing an inherited disorder. Brammer, a contract development and manufacturing organization hired by drug companies to assist them, has nearly 600 employees in Massachusetts and Florida.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy